세계의 홍역, 볼거리, 풍진 백신 시장

Measles, Mumps, Rubella Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Targeted Population, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,286,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,682,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,175,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 홍역, 볼거리, 풍진(MMR) 백신 시장은 2024년에 18억 7,000만 달러로 평가되었고, 2030년에는 30억 4,000만 달러에 도달할 것으로 예측되며, 예측 기간 동안 CAGR 8.42%로 성장할 전망입니다.

기본적인 공중 보건 조치로서 예방 접종에 대한 수요가 증가함에 따라 시장 성장이 촉진되고 있습니다. WHO 및 유니세프와 같은 국제기구의 지원으로 강화된 국가 예방접종 일정에 MMR 백신이 포함되면서 고소득 국가와 저소득 국가 모두에서 백신이 널리 채택되고 있습니다. 특히 취약 계층에서 홍역이 반복적으로 발생하면서 대규모 백신 접종 캠페인의 필요성이 강조되고 있습니다. 의료 인프라 강화, 민관 파트너십, 유통 물류 개선으로 백신 접근성과 보급률이 더욱 향상되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	18억 7,000만 달러
시장 규모(2030년)	30억 4,000만 달러
CAGR(2025-2030년)	8.42%
급성장 부문	소아과 및 개인 의료 클리닉
최대 시장	북미

특히 자원이 제한된 환경에서 열 안정적이고 바늘이 없는 제형을 포함한 백신 전달 방법의 혁신이 성장을 주도하고 있습니다. MMR과 다른 소아 백신을 1회 접종 형태로 결합하는 추세는 예방 접종 일정을 간소화하고 순응도를 개선하고 있습니다. 디지털 의료 시스템과의 통합은 백신 접종 범위와 후속 조치를 추적하여 프로그램 효율성을 향상시키는 데 도움이 되고 있습니다.

시장 성장 촉진요인

정부의 예방 접종 노력 증가

주요 시장 과제

백신 접종 주저와 잘못된 정보

주요 시장 동향

MMR 백신의 보편적 예방접종 프로그램 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 유형별(1가, 3가(혼합형 MMR), 4가)
  • 대상자별(영유아 및 어린이(9개월-12세), 성인)
  • 유통 경로별(병원 및 의료기관, 백신 센터 및 공중 보건 진료소, 소아과 및 개인 의료 클리닉)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카 홍역, 볼거리, 풍진 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

제15장 전략적 제안

제16장 기업 소개와 면책사항

HBR

영문 목차

영문목차

The Global Measles, Mumps, and Rubella (MMR) Vaccine Market was valued at USD 1.87 billion in 2024 and is projected to reach USD 3.04 billion by 2030, growing at a CAGR of 8.42% during the forecast period. Market growth is being fueled by increasing demand for immunization as a fundamental public health measure. The inclusion of MMR vaccines in national immunization schedules, bolstered by support from international agencies such as WHO and UNICEF, has led to widespread adoption in both high- and low-income countries. Recurring outbreaks of measles, especially in underserved populations, highlight the need for large-scale vaccination campaigns. Strengthening healthcare infrastructure, public-private partnerships, and improved distribution logistics are further enhancing vaccine access and coverage.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.87 Billion
Market Size 2030	USD 3.04 Billion
CAGR 2025-2030	8.42%
Fastest Growing Segment	Pediatric and Private Healthcare Clinics
Largest Market	North America

Innovation in vaccine delivery methods, including thermostable and needle-free formulations, is also driving growth, particularly in resource-constrained settings. The trend of combining MMR with other pediatric vaccines into a single-dose format is simplifying immunization schedules and improving adherence. Integration with digital health systems is aiding in tracking vaccination coverage and follow-ups, enhancing program efficiency.

Key Market Drivers

Increasing Government Immunization Initiatives

Government-led immunization initiatives have become a pivotal factor driving the global MMR vaccine market. Countries worldwide are prioritizing vaccine-preventable disease control by integrating MMR into routine childhood immunization programs, often at no cost. Increased funding, improved logistics, and targeted rural outreach are elevating vaccine coverage. Supported by organizations such as WHO, UNICEF, and Gavi, these initiatives are reducing disease incidence and mortality, particularly in low-income nations.

Despite such efforts, global immunization coverage still falls short of WHO's 95% target needed for measles elimination. In 2023, only 83% of children globally received the first measles vaccine dose, while just 74% received the second. Alarmingly, over 22 million children missed their first dose. These figures underline the urgency for governments to scale up immunization efforts through enhanced policies, monitoring, and education, reinforcing sustained demand for MMR vaccines.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, driven by misinformation and distrust, remains a substantial barrier to broader adoption of MMR vaccines. Persistent myths, such as a link between the MMR vaccine and autism, continue to undermine public confidence despite being scientifically disproven. The proliferation of false information via social media and other platforms exacerbates hesitancy, particularly in communities with limited access to reliable healthcare education.

These attitudes delay or reduce vaccine uptake, leading to disease resurgence and undermining public health goals. Overcoming this issue requires coordinated efforts involving community leaders, healthcare providers, and policymakers to promote accurate information and build trust. Tailored education campaigns and transparent communication strategies will be key to addressing misinformation and improving vaccine acceptance across regions.

Key Market Trends

Integration of MMR Vaccines into Universal Immunization Programs

The increasing integration of MMR vaccines into universal immunization programs is a notable trend supporting market expansion. Governments, with backing from global health bodies, are embedding MMR vaccination within broader public health strategies to improve childhood immunization coverage. These efforts are essential in achieving herd immunity and controlling disease outbreaks.

According to WHO, global measles vaccine coverage remains insufficient, with only 83% of children receiving the first dose and 74% the second in 2023. Nearly 35 million children lacked full protection against measles. These gaps emphasize the need for inclusive immunization strategies. As countries intensify efforts to close these coverage gaps, the demand for reliable MMR vaccines is expected to grow significantly.

Key Market Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

Report Scope

In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Measles, Mumps, Rubella Vaccine Market, By Type:

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

Measles, Mumps, Rubella Vaccine Market, By Targeted Population:

• Infants and Children (9 months to 12 years)
• Adults

Measles, Mumps, Rubella Vaccine Market, By Distribution Channel:

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric and Private Healthcare Clinics

Measles, Mumps, Rubella Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Measles, Mumps, Rubella Vaccine Market.

Available Customizations

Global Measles, Mumps, Rubella Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Measles, Mumps, Rubella Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Monovalent, Trivalent (combined MMR), Tetravalent)
  • 5.2.2. By Targeted Population (Infants and children (9 months to 12), Adults)
  • 5.2.3. By Distribution Channel (Hospitals and Healthcare Institutions, Vaccine Centers and Public Health Clinics, Pediatric and Private Healthcare Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Measles, Mumps, Rubella Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Targeted Population
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Targeted Population
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Targeted Population
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Targeted Population
      • 6.3.3.2.3. By Distribution Channel

7. Europe Measles, Mumps, Rubella Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Targeted Population
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Targeted Population
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Targeted Population
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Targeted Population
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Targeted Population
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Targeted Population
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Measles, Mumps, Rubella Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Targeted Population
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Targeted Population
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Targeted Population
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Targeted Population
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Targeted Population
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Targeted Population
      • 8.3.5.2.3. By Distribution Channel

9. South America Measles, Mumps, Rubella Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Targeted Population
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Targeted Population
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Targeted Population
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Targeted Population
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Measles, Mumps, Rubella Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Targeted Population
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Targeted Population
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Targeted Population
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Targeted Population
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. GlaxoSmithKline plc
• 14.3. Pfizer Inc.
• 14.4. Novartis AG
• 14.5. Serum Institute of India Pvt. Ltd.
• 14.6. Panacea Biotec Ltd.
• 14.7. Takeda Pharmaceutical Company Limited
• 14.8. Sinovac Biotech Ltd.
• 14.9. Biological E. Limited
• 14.10. Emergent BioSolutions Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료